CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR THERAPY OF SEVERE CHRONIC EBV I

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 严重慢性EBV感染综合征的发病机制可能与循环抑制因子的存在有关，这些循环抑制因子使EBV特异性T细胞的产生失效以控制EBV感染，并且可以通过离体产生自体EBV特异性CTL并将其过继转移给受体来克服。 本议定书的具体目标是 1)确定静脉注射自体EBV特异性细胞毒性T细胞系在患有严重慢性EBV感染的个体中的安全性，2）确定静脉注射CTL在这些患者中的抗病毒和免疫功效，3）评估这些注射的临床效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The pathogenesis of severe chronic EBV infection syndrome may relate to the presence of circulating inhibitory factors that disable the generation of EBV-specific T cells to control EBV infection and can be overcome by generating autologous EBV specific CTL ex vivo and adoptively transferring them to the recipient. The specific objectives of this protocol are 1) To determine the safety of intravenous injections of autologous EBV specific cytotoxic T cell lines in individuals with severe chronic EBV infection, 2) To determine antiviral and immunological efficacy of intravenous injections of CTLs in these patients, 3) to assess the clinical effects of these injections.